GLP2R抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cells, Primary antibody: P00401(GLP2R Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P00401(GLP2R Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P00401(GLP2R Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The glucagon-like peptide-2 receptor (GLP2R) is a G protein-coupled receptor (GPCR) primarily expressed in the gastrointestinal tract, central nervous system, and select endocrine tissues. It binds glucagon-like peptide-2 (GLP-2), a gut-derived hormone involved in intestinal growth, nutrient absorption, and mucosal repair. GLP2R activation triggers signaling pathways like cAMP/PKA, promoting cell proliferation, inhibiting apoptosis, and enhancing barrier function in the gut.

GLP2R antibodies are critical tools for studying receptor localization, expression patterns, and functional roles in physiological or pathological contexts. They enable applications such as immunohistochemistry, Western blotting, and flow cytometry to map GLP2R distribution in tissues or assess its regulation in diseases like short bowel syndrome, inflammatory bowel disease (IBD), or obesity. Commercially available antibodies target specific epitopes (e.g., extracellular or intracellular domains) and vary by species reactivity (human, mouse, rat).

Research using GLP2R antibodies has clarified its therapeutic relevance. For example, GLP-2 analogs (e.g., teduglutide) exploit GLP2R signaling to treat intestinal insufficiency. Dysregulated GLP2R expression is also linked to metabolic disorders and cancer, highlighting its dual roles in homeostasis and disease. However, challenges remain in validating antibody specificity due to GPCR structural homology and low receptor abundance. Recent advances in monoclonal antibody development and epitope tagging have improved detection reliability, supporting deeper mechanistic insights into GLP2R biology.